Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

×




Memorial Sloan Kettering Cancer Center

About Us Sloan Kettering Institute The Jan Grimm Lab

Research

Cerenkov Imaging

Education & Training




Two PSMA-positive tumors were targeted with radiolabeled J591 anti-PSMA antibody (in collaboration with the Lewis lab) and show excellent uptake on PET (A), which is reflected on the Cerenkov image (B)> There is excellent correlation between the Cerenkov signal and the radiotracer uptake (C).

Cerenkov luminescence imaging (CLI) is an emerging hybrid modality that utilizes the light emission from many commonly used medical isotopes. Cerenkov radiation (CR) is produced when charged particles travel through a dielectric medium faster than the speed of light in that medium. First described in detail nearly 100 years ago, CR has only recently been applied for biomedical imaging purposes. The modality is of considerable interest as it enables the use of widespread luminescence imaging equipment to visualize clinical diagnostic (all PET radioisotopes) and many therapeutic radionuclides. The amount of light detected in CLI applications is significantly lower than in other optical imaging techniques such as bioluminescence and fluorescence. However, significant advantages in technology on the camera detector makes CLI now an interesting methodology certainly for preclinical imaging and possibly also for clinical applications.

The advantages of CLI over other optical imaging agents include the use of approved radiotracers and lack of an incident light source, resulting in high signal to background ratios. As well, multiple subjects may be imaged concurrently (up to 5 in common bioluminescent equipment) and much faster than with PET.

We recently piublished on "Cerenkov 2.0", the utilization of Cerenkov to interrogate different disease signatures using unique and novel imaging agents, which are excited by Cerenkov to indicate antigen expression or - as activatable imaging agents - even to demonstrate enzymatic activity. These agents are inherently quantitative and have a better signal-to noise ratio compared to conventional fluorescence imaging. They also allow for the simultaneous analysis of different molecular entities. This paper has been published online on September 8, 2013 in *Nature Medicine*.

Our lab is interested in various Cerenkov applications, from combining CLI with nanotechnology in the preclinical realm to clinical translation; currently we also have one active clinical trial exploring Cerenkov imaging in patients. From this trial we recently published the first results, demonstrating the feasibility of clinical Cerenkov imaging.



SCIFI (Secondary Cerenkov-induced Fluorescence Imaging) allows true multiumodal imaging of disease signatures.

R01 EB014944-01

Ruggiero A, Holland JP, Lewis JS, Grimm J. "Cerenkov luminescence imaging of medical isotopes." J Nucl Med. 2010 Jul;51(7): 1123-30. Epub 2010 Jun 16.

Holland, JP, Normand, G, Ruggiero, A, Lewis, JS and Grimm, J. "Intraoperative imaging of PET radiotracers using Cerenkov luminescence emissions." Molecular Imaging. 2011;10(3): 177.

Thorek D, Abou D, Beattie B, Bartlett R, Huang R, Zanzonico P, Grimm J. "Positron Lymphography; Multimodal, High-Resolution, Dynamic Mapping and Resection of Lymph Nodes After Intradermal Injection of 18F-FDG." JNM 2012;53(9):1438.

Thorek D, Grimm J. "Enzymatically activatable diagnostic probes." Current Pharmaceutical Biotechnology. 2012 Jan 2. 2(2):163.

Project Members

Edwin C. Pratt

- About Us
Overview
Leadership
Administration

<u>History</u>

Contact Us

Research

Overview

Research programs

Research labs

Core facilities & resources

Education & Training

<u>Overview</u>

Postdoctoral training

Gerstner Sloan Kettering Graduate School

Joint graduate programs

Programs for college & high school students

News & Events

<u>Overview</u>

Seminars & events

Open Positions

<u>Overview</u>

Faculty positions

Postdoctoral positions

Communication preferences Cookie preferences Legal disclaimer Accessibility Statement Privacy policy Public notices © 2024 Memorial Sloan Kettering Cancer Center